Why MedTech Products Don't Sell After Regulatory Approval
Five commercial gaps founders miss across Asia Pacific.
Regulatory approval feels like a finish line.
For many MedTech founders, it marks the moment years of engineering, clinical work and investment finally become something tangible. The product is approved. The technology works. The evidence is strong.
Then sales begin to slow.
Clinicians express interest but orders do not materialise. Distributors say the product looks promising but momentum stalls. Procurement teams ask questions the sales deck never anticipated. Months after launch, founders begin asking a difficult question.
“Why aren't we seeing the commercial traction we expected?”
This is a familiar challenge across MedTech in Asia Pacific.
Whether you're commercialising a medical device, IVD, diagnostics platform or digital health technology, regulatory approval is only one milestone. Sustainable MedTech commercialisation requires customer insight, market positioning and commercial readiness long before sales begin to scale.
One of the biggest misconceptions in medical device commercialisation is believing that regulatory approval automatically creates market adoption. It doesn't.
Regulatory readiness allows a product to enter a market. Commercial readiness determines whether that product gains adoption, generates revenue and creates long-term growth.
For MedTech, medical device and IVD companies, commercial readiness includes Voice of Customer research, commercial strategy, market entry planning, clinical education strategy and commercial enablement before launch.
Gap 1: You know your product better than your customer knows their problem.
Founders naturally become experts in their technology.
Customers are experts in their own clinical, operational and commercial environment.
A clinician may value workflow improvement more than another technical feature.
A procurement manager may care about service reliability, training requirements and total cost of ownership.
A hospital executive may be thinking about patient throughput, budget impact and operational efficiency rather than device specifications.
Every stakeholder is solving a different problem.
That means one commercial message rarely works for everyone.
What problem does each stakeholder believe we solve — in their own words?
Voice of Customer research is not about collecting opinions. It is about understanding the language, priorities and objections that shape real buying decisions across the healthcare ecosystem.
Gap 2: Interest is not adoption.
Many MedTech founders mistake positive conversations for commercial traction.
- “Interesting product.”
- “We'd like to trial it.”
- “Come back after budget planning.”
These are encouraging conversations — but they are not adoption signals.
Commercial traction begins when customers move from curiosity to commitment through:
- clinical evaluation,
- procurement engagement,
- distributor commitment,
- tender inclusion,
- repeat purchasing.
Where exactly is the customer journey stopping?
Understanding where momentum disappears often reveals whether the challenge is clinical education, positioning, pricing, workflow integration or commercial execution.
Gap 3: Asia Pacific is not one MedTech market.
Many founders describe "Asia" as a target market.
In reality, Asia Pacific is a collection of very different healthcare systems and commercial environments.
- reimbursement pathways
- procurement models
- distributor capability
- public versus private healthcare
- competitive pricing
- clinician influence
- tender processes
A market entry strategy that works in one country may fail completely in another.
Which market gives us the highest probability of meaningful early traction?
Gap 4: Your value proposition changes depending on who is listening.
Technical differentiation does not automatically become commercial differentiation.
Customers respond to outcomes, not specifications.
- Faster diagnosis.
- Easier workflow.
- Reduced training burden.
- Operational efficiency.
- Better patient pathways.
Commercial positioning translates technical capability into practical value for multiple decision-makers.
Can every stakeholder explain why this product matters without reading our brochure?
Gap 5: Commercial enablement starts before launch.
Many teams think commercial enablement begins after launch with sales training.
In reality, it starts much earlier.
- Voice of Customer conversations.
- Clinical education strategy.
- Distributor confidence.
- Market messaging.
- Launch materials.
- Commercial alignment.
Is everyone representing the product telling the same commercial story?
Regulatory approval is the beginning, not the end.
A MedTech product can be clinically excellent and commercially unclear at the same time.
That uncertainty often appears as slower sales, hesitant distributors, inconsistent messaging or disappointing market traction after launch.
Rather than assuming the market "doesn't get it", it is often more useful to identify where the commercial gap exists.
Sometimes it is positioning.
Sometimes it is customer understanding.
Sometimes it is market selection.
Sometimes it is commercial execution.
The goal is not more activity. The goal is making better commercial decisions, earlier.
A question worth asking before your next commercial decision
Before investing in another sales campaign, distributor search or market launch, ask yourself one question.
“What evidence do we have that we're solving the right commercial problem?”
The answer often changes the next decision more than another sales presentation does.
That is where commercial clarity begins.